Literature DB >> 28241092

Adherence to National Comprehensive Cancer Network guidelines for time to initiation of postoperative radiation therapy for patients with head and neck cancer.

Evan M Graboyes1, Elizabeth Garrett-Mayer2, Anand K Sharma3, Eric J Lentsch1, Terry A Day1.   

Abstract

BACKGROUND: Adherence to evidence-based treatment guidelines has been proposed as a measure of cancer care quality. The objective of this study was to determine the rate and predictors of care that does not adhere to National Comprehensive Cancer Network guidelines regarding commencing postoperative radiation therapy (PORT) within 6 weeks of surgery for patients with head and neck squamous cell carcinoma (HNSCC).
METHODS: The National Cancer Data Base was reviewed from 2006 to 2014, and patients with HNSCC who underwent curative-intent surgery followed by PORT were identified. Multivariable logistic regression analysis was used to determine the factors associated with nonadherence to guidelines regarding the timing of initiating PORT.
RESULTS: In total, 47,273 patients were included in the study. 55.7% of patients (26,340/47,273) failed to commence PORT within 6 week of surgery. The percentage of patients who failed to initiate PORT within 6 week of surgery increased over time. On multivariable analysis, the factors associated with failure to initiate timely, guideline-adherent PORT included black race, public insurance [Medicare, Medicaid] or uninsured status, lower levels of education, increased severity of comorbidity, increased postoperative length of stay, 30-day unplanned hospital readmission, treatment at an academic medical center, and the receipt of surgery and PORT at different facilities.
CONCLUSIONS: Over 50% of patients with HNSCC who undergo surgery and PORT receive care that does not adhere to National Comprehensive Cancer Network guidelines with regard to initiating PORT within 6 weeks of surgery. Sociodemographic, oncologic, treatment, and hospital factors are all associated with failure to receive guideline-directed care and should be explored in future studies. Cancer 2017;123:2651-60.
© 2017 American Cancer Society. © 2017 American Cancer Society.

Entities:  

Keywords:  NCNN guidelines; National Cancer Data Base; National Comprehensive Cancer Network (NCCN); adherence to guidelines; head and neck quality; quality of care

Mesh:

Year:  2017        PMID: 28241092     DOI: 10.1002/cncr.30651

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

1.  Effect of time to initiation of postoperative radiation therapy on survival in surgically managed head and neck cancer.

Authors:  Evan M Graboyes; Elizabeth Garrett-Mayer; Mark A Ellis; Anand K Sharma; Amy E Wahlquist; Eric J Lentsch; Brian Nussenbaum; Terry A Day
Journal:  Cancer       Date:  2017-08-25       Impact factor: 6.860

2.  Head and Neck Oncology Is on the National Quality Sidelines No Longer-Put Me in, Coach.

Authors:  Evan M Graboyes; Vasu Divi; Brian A Moore
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2022-08-01       Impact factor: 8.961

3.  Barriers to the Delivery of Timely, Guideline-Adherent Adjuvant Therapy Among Patients With Head and Neck Cancer.

Authors:  Evan M Graboyes; Chanita Hughes Halbert; Hong Li; Graham W Warren; Anthony J Alberg; Elizabeth A Calhoun; Brian Nussenbaum; Courtney H Marsh; Jessica McCay; Terry A Day; John M Kaczmar; Anand K Sharma; David M Neskey; Katherine R Sterba
Journal:  JCO Oncol Pract       Date:  2020-08-27

4.  Association of Care Processes With Timely, Equitable Postoperative Radiotherapy in Patients With Surgically Treated Head and Neck Squamous Cell Carcinoma.

Authors:  Tyler A Janz; Joanne Kim; Elizabeth G Hill; Katherine Sterba; Graham Warren; Anand K Sharma; Terry A Day; Chanita Hughes-Halbert; Evan M Graboyes
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-12-01       Impact factor: 6.223

5.  Racial and Ethnic Disparities in Travel for Head and Neck Cancer Treatment and the Impact of Travel Distance on Survival.

Authors:  Evan M Graboyes; Mark A Ellis; Hong Li; John M Kaczmar; Anand K Sharma; Eric J Lentsch; Terry A Day; Chanita Hughes Halbert
Journal:  Cancer       Date:  2018-06-22       Impact factor: 6.860

6.  Association of Medicaid Expansion Under the Affordable Care Act With Stage at Diagnosis and Time to Treatment Initiation for Patients With Head and Neck Squamous Cell Carcinoma.

Authors:  Helmneh M Sineshaw; Mark A Ellis; K Robin Yabroff; Xuesong Han; Ahmedin Jemal; Terry A Day; Evan M Graboyes
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2020-03-01       Impact factor: 6.223

7.  Development and Validation of Nomograms for Predicting Delayed Postoperative Radiotherapy Initiation in Head and Neck Squamous Cell Carcinoma.

Authors:  Dylan A Levy; Hong Li; Katherine R Sterba; Chanita Hughes-Halbert; Graham W Warren; Brian Nussenbaum; Anthony J Alberg; Terry A Day; Evan M Graboyes
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2020-05-01       Impact factor: 6.223

8.  Association of Survival With Shorter Time to Radiation Therapy After Surgery for US Patients With Head and Neck Cancer.

Authors:  Jeremy P Harris; Michelle M Chen; Ryan K Orosco; Davud Sirjani; Vasu Divi; Wendy Hara
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-04-01       Impact factor: 6.223

9.  Development and Evaluation of a Navigation-Based, Multilevel Intervention to Improve the Delivery of Timely, Guideline-Adherent Adjuvant Therapy for Patients With Head and Neck Cancer.

Authors:  Evan M Graboyes; Katherine R Sterba; Hong Li; Graham W Warren; Anthony J Alberg; Elizabeth A Calhoun; Brian Nussenbaum; Jessica McCay; Courtney H Marsh; Nosayaba Osazuwa-Peters; David M Neskey; John M Kaczmar; Anand K Sharma; Jennifer Harper; Terry A Day; Chanita Hughes-Halbert
Journal:  JCO Oncol Pract       Date:  2021-03-10

10.  Adherence to Computer-Assisted Surgical Planning in 136 Maxillofacial Reconstructions.

Authors:  Hongyang Ma; Sohaib Shujaat; Jeroen Van Dessel; Yi Sun; Michel Bila; Jan Vranckx; Constantinus Politis; Reinhilde Jacobs
Journal:  Front Oncol       Date:  2021-07-16       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.